Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC.
In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P<0.0001) and overall survival (OS; HR, 0.68; 95% CI, 0.53-0.87; P=0.00251) with manageable safety and no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all patients randomized in the PACIFIC study. Patients, stratified by age, sex and smoking history, were randomized (2:1) to receive durvalumab 10 mg/kg intravenously every 2 weeks or placebo, up to 12 months. OS was analyzed using a stratified log-rank test in the ITT population. Medians and rates at 12, 24 and 36 months were estimated by Kaplan-Meier method. As of January 31, 2019, 48.2% of patients had died (44.1% and 56.5% in the durvalumab and placebo groups, respectively). Median duration of follow-up was 33.3 months. Updated OS remained consistent with that previously reported (stratified HR 0.69, 95% CI, 0.55-0.86); median OS not reached with durvalumab versus 29.1 months with placebo. The 12-, 24- and 36-month OS rates with durvalumab and placebo were 83.1% versus 74.6%, 66.3% versus 55.3%, and 57.0% versus 43.5%, respectively. All secondary outcomes examined showed improvements consistent with previous analyses. Updated OS data from PACIFIC, including 3-year survival rates, demonstrate the long-term clinical benefit with durvalumab following CRT and further establish the PACIFIC regimen as the standard of care in this population.